Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805419 | 0.91 | MCHR1 (0.39) | MCHR1 | |
| SCHEMBL4414010 | 0.91 | MCHR1 (0.42) | MCHR1MAOBMAOA | |
| SCHEMBL4417228 | 0.90 | GRM5 (0.46) | MCHR1MAOBGRM5MAOAKCNH2 | |
| SCHEMBL4413939 | 0.90 | PRKDC (0.40) | MCHR1 | |
| SCHEMBL4422985 | 0.89 | ADORA3 (0.42) | MCHR1MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4415583 | 0.89 | MCHR1 (0.43) | MCHR1GRM5 | |
| SCHEMBL4413873 | 0.88 | PRKDC (0.37) | MCHR1MAOB | |
| SCHEMBL4800792 | 0.87 | MCHR1 (0.37) | MCHR1 | |
| SCHEMBL4551641 | 0.87 | MCHR1 (0.41) | MCHR1 | |
| SCHEMBL4413929 | 0.86 | KCNH2 (0.36) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
| EP-1857443-A2 | Therapeutic morpholino-substituted compounds | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-6977255-B2 | Therapeutic morpholino-substituted compounds | KINACIA PTY. LTD. (AU) | 2005-12-20 | — | — | US | disclosed |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD. | 2005-04-21 | — | — | US | disclosed |
| EP-1257537-A4 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD (AU) | 2003-04-23 | — | — | EP | disclosed |
| EP-1257537-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | Kinacia Pty Ltd (AU) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001053266-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD. (AU) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | PIK3CA, PTK2, PDPK1 | MCHR1 4703/4885MAPK14 454/4885MAOB 3525/4885 |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | MCHR1 4701/4885MAPK14 457/4885MAOB 3490/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | MCHR1 4701/4885MAPK14 457/4885MAOB 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.